MX2022013808A - Terapia de combinacion triple para mejorar la eliminacion de celulas cancerigenas en canceres con baja inmunogenicidad. - Google Patents
Terapia de combinacion triple para mejorar la eliminacion de celulas cancerigenas en canceres con baja inmunogenicidad.Info
- Publication number
- MX2022013808A MX2022013808A MX2022013808A MX2022013808A MX2022013808A MX 2022013808 A MX2022013808 A MX 2022013808A MX 2022013808 A MX2022013808 A MX 2022013808A MX 2022013808 A MX2022013808 A MX 2022013808A MX 2022013808 A MX2022013808 A MX 2022013808A
- Authority
- MX
- Mexico
- Prior art keywords
- cancers
- cancer cell
- combination therapy
- cell killing
- low immunogenicity
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000005847 immunogenicity Effects 0.000 title abstract 2
- 230000005880 cancer cell killing Effects 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 238000011295 triple combination therapy Methods 0.000 title 1
- 101100503323 Artemisia annua FPS1 gene Proteins 0.000 abstract 2
- 101100503326 Gibberella fujikuroi FPPS gene Proteins 0.000 abstract 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229940126530 T cell activator Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 abstract 1
- 229950011498 plinabulin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
En La presente se describen composiciones y métodos de tratamiento de una condición donde se desea una mejor inmunogenicidad. Algunas modalidades descritas en la presente se relacionan con composiciones que comprenden un activador y/o proliferador de células T, uno o más inhibidores de puntos de control inmune y un inhibidor de FPPS. Algunas modalidades se relacionan con métodos de tratamiento del cáncer mediante la coadministración de plinabulina, uno o más inhibidores de puntos de control inmune y un inhibidor de FPPS a un sujeto que lo necesita.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063019703P | 2020-05-04 | 2020-05-04 | |
| PCT/US2021/030324 WO2021225908A1 (en) | 2020-05-04 | 2021-04-30 | Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013808A true MX2022013808A (es) | 2023-02-09 |
Family
ID=78468279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013808A MX2022013808A (es) | 2020-05-04 | 2021-04-30 | Terapia de combinacion triple para mejorar la eliminacion de celulas cancerigenas en canceres con baja inmunogenicidad. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230181605A1 (es) |
| EP (1) | EP4146216A4 (es) |
| JP (1) | JP2023524530A (es) |
| KR (1) | KR20230006568A (es) |
| CN (1) | CN113891714A (es) |
| AU (1) | AU2021266969A1 (es) |
| BR (1) | BR112022022401A2 (es) |
| CA (1) | CA3182148A1 (es) |
| IL (1) | IL297884A (es) |
| MX (1) | MX2022013808A (es) |
| WO (1) | WO2021225908A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102626155B1 (ko) | 2015-03-06 | 2024-01-17 | 비욘드스프링 파마수티컬스, 인코포레이티드. | Ras 돌연변이와 관련된 암의 치료 방법 |
| KR20180100585A (ko) | 2015-12-22 | 2018-09-11 | 인사이트 코포레이션 | 면역조절제로서의 헤테로사이클릭 화합물 |
| CA3013467A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| LT3472167T (lt) | 2016-06-20 | 2022-11-10 | Incyte Corporation | Heterocikliniai junginiai kaip imunomoduliatoriai |
| JP7350015B2 (ja) | 2018-01-24 | 2023-09-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリンの投与による血小板減少症を軽減するための組成物および方法 |
| JP2023548859A (ja) | 2020-11-06 | 2023-11-21 | インサイト・コーポレイション | Ｐｄ－１／ｐｄ－ｌ１阻害剤ならびにその塩及び結晶形態を作製するためのプロセス |
| WO2022133492A1 (en) * | 2020-12-18 | 2022-06-23 | Beyondspring Pharmaceuticals, Inc. | Compositions and methods for generating anti-tumor immune response |
| US20230149409A1 (en) * | 2021-09-24 | 2023-05-18 | Incyte Corporation | Treatment of human papillomavirus-associated cancers by pd-l1 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| WO2015104292A2 (en) * | 2014-01-07 | 2015-07-16 | Biomedical Research Foundation Of The Academy Of Athens | Compounds for use in treating or preventing cancerous diseases |
| WO2016081281A1 (en) * | 2014-11-17 | 2016-05-26 | Salk Institute For Biological Studies | Lipophilic bisphosphonates and methods of use |
| MY193968A (en) * | 2015-02-12 | 2022-11-03 | Beyondspring Pharmaceuticals Inc | Use of plinabulin in combination with immune checkpoint inhibitors |
| CA3013467A1 (en) * | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| CN110603037A (zh) * | 2017-03-13 | 2019-12-20 | 大连万春布林医药有限公司 | 普那布林的组合物及其用途 |
| US10933061B2 (en) * | 2017-12-21 | 2021-03-02 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate therapies and methods of use |
| JP7372253B2 (ja) * | 2018-04-05 | 2023-10-31 | ノビガ・リサーチ・エービー | 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ |
-
2021
- 2021-04-30 US US17/923,189 patent/US20230181605A1/en active Pending
- 2021-04-30 KR KR1020227042503A patent/KR20230006568A/ko active Search and Examination
- 2021-04-30 AU AU2021266969A patent/AU2021266969A1/en active Pending
- 2021-04-30 CN CN202180002916.9A patent/CN113891714A/zh active Pending
- 2021-04-30 WO PCT/US2021/030324 patent/WO2021225908A1/en unknown
- 2021-04-30 JP JP2022567150A patent/JP2023524530A/ja active Pending
- 2021-04-30 EP EP21800499.2A patent/EP4146216A4/en active Pending
- 2021-04-30 BR BR112022022401A patent/BR112022022401A2/pt unknown
- 2021-04-30 IL IL297884A patent/IL297884A/en unknown
- 2021-04-30 MX MX2022013808A patent/MX2022013808A/es unknown
- 2021-04-30 CA CA3182148A patent/CA3182148A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021266969A1 (en) | 2022-12-08 |
| CN113891714A (zh) | 2022-01-04 |
| US20230181605A1 (en) | 2023-06-15 |
| EP4146216A1 (en) | 2023-03-15 |
| WO2021225908A1 (en) | 2021-11-11 |
| KR20230006568A (ko) | 2023-01-10 |
| EP4146216A4 (en) | 2024-05-29 |
| IL297884A (en) | 2023-01-01 |
| JP2023524530A (ja) | 2023-06-12 |
| BR112022022401A2 (pt) | 2022-12-13 |
| CA3182148A1 (en) | 2021-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022013808A (es) | Terapia de combinacion triple para mejorar la eliminacion de celulas cancerigenas en canceres con baja inmunogenicidad. | |
| PH12019502132A1 (en) | Combination therapy for the treatment or prevention of tumours | |
| MX2020009773A (es) | Terapia de combinacion. | |
| WO2020236825A3 (en) | Mcl-1 inhibitor antibody-drug conjugates and methods of use | |
| CR20220082A (es) | N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos | |
| IN2012DN01964A (es) | ||
| MX2022009347A (es) | Terapia de combinacion para el tratamiento del crecimiento celular anormal. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| MX2022012351A (es) | Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres. | |
| MX2023004032A (es) | Terapias inmuno-oncologicas con conjugados de il-2. | |
| MX2021005240A (es) | Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer. | |
| MX2023005192A (es) | Composicion que comprende una combinacion de inhibidor de punto de control inmunitario y conjugado de anticuerpo-amatoxina para uso en la terapia del cancer. | |
| CL2023003090A1 (es) | Combinaciones de composiciones terapéuticas y usos para tratar cánceres | |
| BR112022026247A2 (pt) | Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer | |
| WO2023009834A3 (en) | Methods of treating cancer | |
| MX2022014886A (es) | Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino. | |
| MX2022012919A (es) | Anticuerpos anti-flt3 y composiciones. | |
| BR112022012821A2 (pt) | Agente de ligação a ccr5 para tratamento de câncer metastático positivo para ccr5 | |
| MX2021011610A (es) | Combinaciones de iadademstat para terapia contra el cancer. | |
| CA3156680A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME | |
| MX2022009399A (es) | Formulacion topica de roflumilast que tiene mayor liberacion y semivida plasmatica. | |
| JOP20220339A1 (ar) | طرق وتركيبات علاج الإسهال الناتج عن العلاج الكيميائي | |
| MX2021001084A (es) | Terapia de combinacion para el tratamiento del cancer. | |
| MX2021001081A (es) | Terapia de combinacion para el tratamiento del cancer. |